LAPTM5 Down (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with LAPTM5 Down.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with LAPTM5 Down.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with LAPTM5 Down.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with LAPTM5 Down.

Results found

Linked to

 

Label

Description

 

Gene

ENSG00000025434 - nuclear receptor subfamily 1 group H member 3

Gene

ENSG00000120458 - Myb/SANT DNA binding domain containing 2

Gene

ENSG00000133019 - cholinergic receptor muscarinic 3

Gene

ENSG00000174227 - phosphatidylinositol glycan anchor biosynthesis class G (EMM blood group)

Gene

ENSG00000176809 - leucine rich repeat containing 37 member A3

Gene

ENSG00000132467 - UTP3 small subunit processome component

Gene

ENSG00000109445 - nucleolar atypical zinc finger

  • Gene

    ENSG00000025434 - nuclear receptor subfamily 1 group H member 3


  • Gene

    ENSG00000120458 - Myb/SANT DNA binding domain containing 2


  • Gene

    ENSG00000133019 - cholinergic receptor muscarinic 3


  • Gene

    ENSG00000174227 - phosphatidylinositol glycan anchor biosynthesis class G (EMM blood group)


  • Gene

    ENSG00000176809 - leucine rich repeat containing 37 member A3


  • Gene

    ENSG00000132467 - UTP3 small subunit processome component


  • Gene

    ENSG00000109445 - nucleolar atypical zinc finger

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.